NCT06879340View on ClinicalTrials.gov

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

March 31, 2030

Study Completion Date

March 31, 2040

Conditions
B-Cell Non-Hodgkin LymphomaB-cell Acute Lymphoblastic Leukemia
Interventions
DRUG

DuoCAR20.19.22-D95

Patient derived autologous T cells, lentiviral transduced to generate, using the Miltenyi CliniMACS Prodigy® closed transduction system, a Duo-CAR-T cells targeting cell surface antigens CD19/20/22.

DRUG

Fludarabine (Conditional therapy)

Lymphodepletion chemotherapy

DRUG

Cyclophosphamide (Conditional therapy)

Lymphodepletion chemotherapy

Trial Locations (1)

66205

RECRUITING

University of Kansas Cancer Center, Westwood

All Listed Sponsors
lead

University of Kansas Medical Center

OTHER